Marksans Pharma Reports Strong Financial Results for FY26, Achieving Historic Revenue and PAT
Marksans Pharma Ltd. announced its financial results for the quarter and full year ending March 31, 2026. The company reported significant growth across key metrics, with the Managing Director highlighting milestone performance in revenue, EBITDA, and profit after tax (PAT).Mark Saldanha, Managing Director of the Company, stated that Fiscal Year 2026 was a milestone year, achieving total income of approximately ₹3,033 crore, EBITDA of ₹601 crore (a margin of 20.4%), and an all-time high PAT of ₹420 crore.
The growth was attributed to several factors, including new launches across various markets, a strong recovery in the UK in Q4, and the launch of 112 new Stock Keeping Units (SKUs) in the US market. The company also expanded its global presence by entering new markets, including Germany, Canada, and Ireland. Marksans Pharma concluded the year with a cash balance of approximately ₹990 crore, maintaining its record of positive net cash flow, with the major capital expenditure cycle nearing completion.
Financial Performance Review
Marksans Pharma's performance showed robust year-over-year growth. The company reported consolidated financial results for FY26 and Q4FY26, detailed below:| Metric | Q4FY26 (Rs. Cr.) | Q4FY25 (Rs. Cr.) | FY26 (Rs. Cr.) | YoY Growth (FY26) |
|---|---|---|---|---|
| Total Income (Net Income) | 891.3 | 723.8 | 3,033.5 | 12.8% |
| Operating Revenue | 856.1 | 708.5 | 2,950.9 | 12.5% |
| Gross Profit | 465.5 | 383.2 | 1,673.7 | 13.2% |
| EBITDA | 195.4 | 126.9 | 600.8 | 12.8% |
| PAT | 149.0 | 90.7 | 420.1 | 9.8% |
| EPS (Rs.) | 3.3 | 2.0 | 9.2 | 9.8% |
The Gross Profit margin for the full year stood at 56.7%, while the EBITDA margin was 20.4%.
Business Segment Performance
The revenue growth was diversified across key geographical markets:| Business Segment | Q4FY26 Revenue (Rs. Cr.) | FY26 Revenue (Rs. Cr.) | YoY Growth (FY26) | Contribution to Revenue |
|---|---|---|---|---|
| US and North America | 406.2 | 1,533.5 | 24.0% | 52.0% |
| UK and Europe | 307.7 | 1,015 | -1.4% | 34.4% |
| Australia and New Zealand | 123.4 | 303.1 | 19.9% | 10.3% |
| Rest of World (RoW) | 18.9 | 99.4 | -4.1% | 3.4% |
| Total Revenue | 856.1 | 2,950.9 | 12.5% | 100.0% |
In the US and North America Formulation business, revenue scaled 2.4x from FY22 to FY26, supported by 100+ products manufactured and distributed. Furthermore, the company launched 112 new SKUs in FY26, with a pipeline of 51 products.
The UK and Europe Formulation business reported that price erosion in UK products stabilized during Q4FY26. In Australia and New Zealand, the revenue of ₹303 crore in FY26 marked a highest-ever quarterly performance, more than doubling sequentially from Q3, driven by new launches. The company also launched its Branded Prescription Division, Nova Pharma, and launched 11 Rx brands in FY26 under this division.
Operational and Financial Highlights
Beyond segment-wise performance, the company reported several key operational metrics for FY26:- Cash generated from operations was ₹458 crore.
- Capex incurred on a net basis was ₹131 crore.
- The working capital cycle stood at approximately 138 days.
- Research & Development (R&D) spending amounted to ₹89 crore in FY26, representing 3.0% of consolidated revenue.
The company stated that the overall momentum, balance sheet strength, and disciplined execution position Marksans Pharma to continue delivering sustainable growth and long-term shareholder value.
MARKSANS Stock Price Movement
Today, Marksans Pharma Limited shares rallied, gaining 12.91% to settle at ₹277.12. The stock saw significant activity during the session, with a robust trading volume reaching 28.65 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: